Jonathan Wolleben, an analyst at JMP Securities, continues to show confidence in Mirum Pharmaceuticals (NASDAQ:MIRM) by maintaining a Market Outperform rating and raising the price target to $69 on February 29, 2024. This decision comes after a series of positive actions taken by JMP Securities towards Mirum Pharmaceuticals, such as initiating coverage with a Market Outperform rating on September 20, 2023, reiterating the Market Outperform recommendation on October 18, 2023, and maintaining the Market Outperform status with a $64 price target on January 11, 2024. Another report also reveals that JMP Securities started coverage on Mirum Pharmaceuticals with a Market Outperform rating and a price target of $70. These consistent endorsements and the increase in price target demonstrate the strong belief in Mirum Pharmaceuticals’ potential for success in the market.
Mirum Pharmaceuticals Inc. (MIRM) Stock Performance Update: February 29, 2024
On February 29, 2024, Mirum Pharmaceuticals Inc. (MIRM) experienced a slight decline in its stock performance. According to data from CNN Money, MIRM is currently trading in the middle of its 52-week range and above its 200-day simple moving average, indicating a relatively stable position in the market.
The price of MIRM shares decreased by $0.25 since the market last closed, representing a 0.87% drop in value. The stock opened at $28.59, which was $0.30 lower than its previous close. This lower opening price may have contributed to the overall decline in the stock’s performance for the day.
Despite the decrease in value, MIRM remains within its 52-week range and above its 200-day moving average, suggesting that the stock may still have potential for growth in the future. Investors should continue to monitor MIRM’s performance and consider factors such as market trends, company developments, and industry news when making investment decisions.
MIRM Stock Performance Review: Revenue Growth Amid Decline in Net Income
MIRM stock had a mixed performance on February 29, 2024, as the company reported its financial results for the past year and the third quarter. According to data from CNN Money, MIRM’s total revenue for the past year was $77.06 million, which represents a significant increase of 302.66% compared to the previous year. In the third quarter, total revenue was $47.73 million, showing a 27.28% increase compared to the previous quarter. MIRM reported a net income of -$135.66 million for the past year, which represents a decrease of 61.53% compared to the previous year. However, in the third quarter, the net income improved to -$23.59 million, showing a 68.14% increase compared to the previous quarter. In terms of earnings per share (EPS), MIRM reported a negative EPS of -$4.02 for the past year, which represents a decrease of 45.1% compared to the previous year. However, in the third quarter, the EPS improved to -$0.57, showing a significant increase of 70.46% compared to the previous quarter. Overall, MIRM’s financial performance on February 29, 2024, showed a mixed picture with strong revenue growth but a decline in net income and EPS compared to the previous year. Investors will be closely monitoring the company’s future earnings reports to see if the positive revenue growth can translate into improved profitability in the coming quarters.
